Related Experiment Video
Updated: Jul 11, 2025

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
Syndecan-1: A Novel Diagnostic and Therapeutic Target in Liver Diseases
Xiaoli Zhang1,2, Yalei Zhao1,2, Liangru Liu1,2
1Department of Infectious Diseases, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Abstract:
Syndecan-1 (SDC-1), known as a coreceptor of various growth factors or an integrin binding partner, regulates various cell behaviours. Under certain pathological conditions, SDC-1 is shed from the cell surface and plays a protective or pathogenic role in various diseases. In the liver, SDC-1 is highly expressed in hepatocytes, where it is localized on the basolateral surface. It is critical to the cellular and molecular functions of hepatocytes, including their attachment to hepatitis viruses. Previous studies have reported that SDC-1 may function as a novel and promising diagnostic and therapeutic marker for various liver diseases, such as drug-induced liver injury, liver fibrosis, and liver cancer. In this review, we summarize related research and highlight the mechanisms by which SDC-1 participates in the pathogenesis of liver diseases, as well as its potential diagnostic and therapeutic applications. This review is expected to lay the foundation for further therapeutic strategies to target SDC-1 in liver diseases.
Insights
Syndecan-1 (SDC-1) is crucial for liver cell functions and viral attachment. Shed SDC-1 plays roles in liver diseases, offering potential as a diagnostic and therapeutic target.
Area of Science:
- Hepatology and Cell Biology
- Molecular Medicine
Background:
- Syndecan-1 (SDC-1) is a cell surface proteoglycan involved in growth factor signaling and cell adhesion.
- In liver cells (hepatocytes), SDC-1 is vital for cellular functions and hepatitis virus attachment.
- Shedding of SDC-1 during pathological conditions influences disease progression.
Approach:
- This review synthesizes current research on Syndecan-1's role in liver diseases.
- Mechanisms of SDC-1 involvement in liver disease pathogenesis are highlighted.
- Potential diagnostic and therapeutic applications of SDC-1 are discussed.
Key Points:
- SDC-1 regulates hepatocyte behavior and is implicated in liver diseases like fibrosis and cancer.
- Shed SDC-1 can exert protective or detrimental effects in various pathologies.
- SDC-1's role in hepatitis virus binding underscores its significance in liver infections.
Conclusions:
- Syndecan-1 is a promising biomarker for diagnosing liver conditions.
- Targeting SDC-1 presents a potential therapeutic strategy for liver diseases.
- Further research into SDC-1 mechanisms can inform novel treatment approaches.
More Related Videos
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...

